See Big Events by Subscribing to Premium
See Short Seller Reports by Subscribing to Premium
Ask anything related to PLX. [ FAQ on what and how to ask] For non-PLX questions, click the logo in the upper-right corner to return to the main page and ask there.
See Competitors by Subscribing to Premium
See YouTube Video by Subscribing to Premium
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Address: 2 University Plaza, Suite 100, Hackensack, NJ, United States, 07601
Employees: 226
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
President, CEO & Director
Senior VP, CFO Treasurer & Secretary
SVP & COO
Vice President of Human Resources
My Watchlist
